Literature DB >> 20704588

Recurrent idiopathic neuroretinitis: natural history and effect of treatment.

Seema V Sundaram1, Valerie A Purvin, Aki Kawasaki.   

Abstract

BACKGROUND: Previous reports have emphasized the self-limited nature of idiopathic neuroretinitis. There is less information about a subgroup of patients who suffer recurrent episodes with worse visual outcome. We sought to better characterize the clinical features of recurrent idiopathic neuroretinitis including the effects of immunosuppressive treatment.
METHODS: Retrospective chart review of neuroretinitis patients from a single institution from 1983 to 2008. Inclusion criteria included two or more episodes of acute visual loss with disc oedema and macular exudates in a star pattern. Cases due to a specific infectious or inflammatory aetiology were excluded.
RESULTS: Forty-one patients were included with an average follow up of 67 months. Median age at the time of the first episode was 28 years (range 10-54 years). Attacks were bilateral sequential in 34 patients (83%). We documented a total of 147 episodes in 75 eyes with an average of 3.6 attacks per patient. The average interval between attacks was 3 years. Visual field loss had a nerve fibre bundle pattern in most cases. Only 36% of eyes retained 6/12 or better visual acuity and greater than two-thirds of their visual field. Long-term immunosuppressive treatment in 13 patients decreased the attack rate by 72%.
CONCLUSIONS: Recurrent idiopathic neuroretinitis typically affects young adults, with no gender preference. Recovery is limited and visual loss is cumulative with repeated attacks, often resulting in severe permanent visual loss. Immunosuppressive treatment appears to lessen the attack frequency.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20704588     DOI: 10.1111/j.1442-9071.2010.02298.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  3 in total

Review 1.  Treatment Strategies for Neuroretinitis: Current Options and Emerging Therapies.

Authors:  Aaron M Fairbanks; Matthew R Starr; John J Chen; M Tariq Bhatti
Journal:  Curr Treat Options Neurol       Date:  2019-07-05       Impact factor: 3.972

Review 2.  Treatment options for atypical optic neuritis.

Authors:  Amina Malik; Maryam Ahmed; Karl Golnik
Journal:  Indian J Ophthalmol       Date:  2014-10       Impact factor: 1.848

3.  Leber's idiopathic stellate neuroretinitis: A clinical case.

Authors:  O Nabih; L Arab; L El Maaloum; B Allali; A El Kettani
Journal:  Ann Med Surg (Lond)       Date:  2022-03-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.